58 results about "Enhancing Antibodies" patented technology

The invention belongs to the field of biology, and discloses an anti-human FcRn VHH antibody and application thereof. The complementarity determining regions CDR1-CDR3 of the VHH antibody are as shown in SEQ ID NO. 1 to SEQ ID NO. 9. The anti-human FcRn VHH antibody of some embodiments of the invention can be specifically combined with human FcRn; the antibody can replace a traditional antibody to be applied to treatment and diagnosis of autoimmune diseases; the fused Fc fragment is combined with an FcRn receptor in a targeting manner, so that the half-life period of IgG in blood is effectively shortened while the targeting property of the antibody is enhanced. According to some examples of the anti-human FcRn VHH antibody, the affinity of the anti-human FcRn VHH antibody and an FcRn receptor can be increased by fusing an Fc fragment, the half-life period of IgG in autoimmune diseases is effectively shortened, and meanwhile the ADCC and CDC effects are relieved.

Herein are antibodies or antigen-binding fragments specifically binding to GPRC5D. Additionally, monovalent antibodies or antigen-binding fragments specifically binding to GPRC5D are also included. The Fc region of these antibodies contains K248E and T437R mutations (designated as "RE mutations") per the EU numbering system. The described antibodies, expressed in host cells that lack fucosylation capabilities, exhibit enhanced antibody¬ dependent cellular cytotoxicity (ADCC) and enhanced complement-dependent cytotoxicity (CDC).

Antibodies with novel Fc modification combinations that increase antibody function are described. The novel Fc modification combinations include M252Y / S254T / T256E (YTE) in combination with M428L / N434S (LS) (YTE+LS), YTE+LS in combination with S239D / A330L / I332E (OLE) (YTE+LS+DLE), YTE+LS in combination with G236A / A330L / I332E (YTE+LS+ALE), YTE+LS in combination with G236A / S239D / A330L (DAL) (YTE+LS+DAL) and YTE+LS in combination with G236A / S239D / A330L / I332E (DALE) (YTE+LS+DALE). Glycosylation modifications are optionally included with these combinations.

Herein are antibodies or antigen-binding fragments specifically binding to GPRC5D. Additionally, monovalent antibodies or antigen-binding fragments specifically binding to GPRC5D are also included. The Fc region of these antibodies contains K248E and T437R mutations (designated as “RE mutations”) per the EU numbering system. The described antibodies, expressed in host cells that lack fucosylation capabilities, exhibit enhanced antibody-dependent cellular cytotoxicity (ADCC) and enhanced complement-dependent cytotoxicity (CDC).

To provide methods and compositions of preferentially enhancing in a subject an antibody-dependent cell-mediated cytotoxicity (ADCC) antibody response to a vaccine for an infectious substance.SOLUTION: Provided is a method comprising administering a herpesvirus entry mediator (HVEM) agonist, a tumor necrosis factor superfamily 14 (TNFSF-14) agonist, or a combination thereof.SELECTED DRAWING: Figure 1A

The present invention relates to a mammalian cell comprising a gene encoding a polypeptide of interest, wherein the polypeptide of interest is expressed comprising one or more posttranslational modification patterns. These modifications are useful for example in glycoprotein production where the antibodies with the modifications have an enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). The present invention also relates to methods for producing the glycoproteins and compositions comprising the glycoproteins, and their uses.

The present invention discloses a method for enhancing antibody immobilization in an avian reovirus detection sensor. The present invention provides a preparation method for an electrochemical immunosensor for detecting reovirus, comprising the following steps: (1) treating the electrode; (2) modifying the electrode with a nanocomposite; (3) pre-treating before antibody immobilization; (4) antibody immobilization; (5) working electrode and detection. The nanocomposite is a gold-platinum nanocomposite, and the pre-treatment is incubation with a cysteamine hydrochloride solution. It is experimentally proven that the detection linear range of the sensor of the present invention is from 0 to 10 5.82 EID 50 / mL, and the lowest detection limit is 10 0.46 EID 50 / mL. Compared with the method of directly immobilizing antibodies, the detection linear range is increased by 10 times, and it has high sensitivity and good specificity.

The present invention relates to improved antibodies targeting CD163. In particular, the present invention relates to improved antibodies targeting CD163 with improved capabilities in relation to inducing Antibody-Dependent Cell-mediated Cytotoxicity (ADCC).

The invention relates to the technical field of immunization. The invention discloses parabacteroides dieldrii and parabacteroides goldsteinii, an application of the parabacteroides dieldrii and / or the parabacteroides goldsteinii in preparation of an immunopotentiator of a vaccine, and the immunopotentiator of the vaccine, and particularly discloses the parabacteroides dieldrii and the parabacteroides goldsteinii, the application of the parabacteroides dieldrii and / or the parabacteroides goldsteinii in preparation of the immunopotentiator of the vaccine. The parabacteroides dieldrii and / or the parabacteroides gold can be used as an immunopotentiator, can activate immunity, enhance antibody titer and shorten antibody generation reaction time, and can remarkably promote proliferation of B cells, plasma cells and memory B cell subgroups in a hair growth center.

The invention discloses a halogen modified hapten for enhancing antibody titer and affinity as well as a preparation method and application of the halogen modified hapten, and belongs to the technical field of biochemical engineering. According to the method, an amantadine structure is innovatively and chemically modified, various halogens such as fluorine, chlorine and bromine are introduced, the AMA halogen modified hapten shown in the formula (I) is formed, and the traditional'most similar 'design principle is broken through. Compared with an unmodified hapten, the hapten modified by halogen in the invention has the advantages that the titer of the polyclonal antibody on amantadine can be obviously improved by 3.4-14 times; wherein the haptens A5 and A6 can obviously improve the titer of the monoclonal antibody to amantadine by 3-18 times, and the affinity is improved by 10.8-16.1 times. The invention provides a new thought and a new method for the rational design of the hapten of the small molecule compound and the preparation of the high-affinity antibody, and the related halogen modification type and quantity strategy can also provide valuable reference for the design of the hapten of other small molecule compounds.

The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

Disclosed herein are cells (e.g, immune cells such as T cells) engineered to contain and / or express a Lysis Sensor Receptors (LSR) comprising an extracellular domain with affinity and specificity for an intracellular product of a diseased cell such as a cancer cell; a transmembrane element and at least one signaling element, and a chimeric antigen receptor (CAR) comprising an extracellular domain with affinity and specificity for an extracellular product of a diseased cell such as a cancer cell; a transmembrane element and at least one signaling element. Also provided herein are various uses of such engineered cells, including in the treatment of cancer, for example to enhance T cell activity (e.g, TIL and / or CAR-T cell activity) and / or to enhance antibody-based therapy, such as cancer immunotherapy.

The present invention relates to the identification of key residues within mouse IgG3 antibodies (mAbs) that are responsible for intermolecular cooperativity and their transfer into IgG1 antibodies in order to enhance their functional affinity and direct a cell killing.

The present invention relates to affinity enhanced antibodies that specifically bind to BCMA and antibodies comprising the P329G mutation, as well as complexes, fusions, bispecific antibodies or pharmaceutical compositions comprising said antibodies. The present invention also relates to nucleic acids encoding said antibodies and host cells comprising said nucleic acids, as well as methods for producing said antibodies. The present invention further relates to therapeutic and diagnostic uses of these antibodies that bind to BCMA.

This application relates to general glycoform compositions and methods for enhancing antibody efficacy. The present invention relates to compositions comprising an antibody or a binding fragment thereof, further comprising a general Fc glycoform, and methods of use.

Provided herein are methods and apparatuses for analyzing mixed formulations of proteins and protein conjugates thereof. Some embodiments of the protein can be conjugated to a moiety, such as a HEMA-PC polymer. Some embodiments of the antibody conjugates can retain or enhance antibody activity. The antibody and conjugate thereof can be particularly useful for treating diabetic retinopathy.

This article describes antibodies or antigen-binding fragments that specifically bind to GPRC5D. Additionally, it includes monovalent antibodies or antigen-binding fragments that specifically bind to GPRC5D. The Fc regions of these antibodies contain K248E and T437R mutations (referred to as “RE mutations”) according to the EU numbering system. The described antibodies, when expressed in host cells lacking fucosylation capacity, exhibit enhanced antibody-dependent cytotoxicity (ADCC) and enhanced complement-dependent cytotoxicity (CDC).

The invention provides a preparation method of an antibody conjugate containing an sLeX tetrasaccharide structure, which comprises the following steps: S1, sequentially adding Endo S2 enzyme and alpha-L-fucosidase into a target antibody, and respectively analyzing glycosylation to avoid modification site conflict or carbohydrate chain structure interference; s2, adding the accurately represented antibody in the S1, B4GalT1 and UDP-Gal into a Tris-HCl system containing Mn < 2 + >, and incubating to obtain a reaction solution I; s3, the reaction liquid I, ST3Gal3, CMP-Neu5Ac and Tris-HCl containing Mg < 2 + > are taken and mixed, and incubation is carried out; adding CMP-N-acyl neuraminic acid phosphodiesterase for reaction, and purifying Protein A to obtain a purified antibody I; s4, the purified antibody I, alpha1, 3 FucT-2HR, GDP-Fuc and Tris-HCl containing Mg < 2 + > are taken and mixed, and incubation is performed; and purifying Protein A to obtain a target product. According to the modified antibody obtained by the invention, while the targeting property is improved, the binding affinity of the antibody and a tumor cell surface antigen can be enhanced, so that the immune blocking activity of the antibody is further enhanced, and dual improvement of the targeting property and the activity is realized.

The invention belongs to the technical field of biological medicine, and particularly relates to a macrophage bionic vesicle nano preparation as well as a preparation method and application thereof. The invention provides a macrophage bionic vesicle nano preparation, which is characterized in that a tumor targeting peptide is used for modifying a macrophage bionic vesicle, and a targeting NSUN family methyltransferase siRNA (small interfering Ribonucleic Acid) is wrapped. The macrophage bionic vesicles modified by the tumor targeting peptide have good gastric cancer cell targeting property, the NSUN expression level of gastric cancer cells can be inhibited by wrapping targeted NSUN family methyltransferase siRNA, the abnormal modification level of gastric cancer m5C is reduced, and the effect of enhancing the treatment of the gastric cancer by the PD-1 antibody is achieved. The results of the embodiment show that the macrophage bionic vesicle nano preparation provided by the invention acts on gastric cancer cells, and can specifically target the gastric cancer cells, induce ferroptosis of the gastric cancer cells, improve the curative effect of a PD-1 antibody, prolong the survival time of mice and improve the tumor immune microenvironment.

The present invention provides a covalent conjugate. The conjugate includes an antibody or antibody derivative, at least two LL37-derived polypeptides, and a payload. The antibody or antibody derivative targets a cell that has phosphatidylserine in its outer leaflet. The payload includes: a small molecule cytotoxic drug of less than 3 kDa, or a plurality thereof; or a peptide or protein of less than 100 kDa. Uses and methods of using these covalent conjugates are also provided, related to enhancing delivery of the antibody / derivative or the payload, e.g. to enhance therapeutic or diagnostic effectiveness.

This invention relates to improving cancer treatment methods using PD-1 / PD-L1 antibodies. In particular, this invention is based on the finding that patients with a TGFβ-specific T cell response are likely to show favorable outcomes in cancer treatment with PD-1 / PD-L1 antibodies. Therefore, this invention provides treatment for such patient groups with PD-1 / PD-L1 antibodies and actively promotes the TGFβ-specific T cell response in order to enhance the therapeutic effect of PD-1 / PD-L1 antibodies.

The present application relates to the technical field of bio-chemical engineering, and particularly relates to a halogen-modified hapten for enhancing antibody affinity, and a preparation method and application thereof. The present application provides a halogen-modified sulfonamide hapten for enhancing antibody affinity, which is obtained by adopting halogen-modified sulfonamides, and the antibody prepared by the halogen-modified sulfonamide hapten has relatively high titer and affinity. The present application provides a new and effective approach for preparing high-affinity sulfonamide antibodies.

Provided herein are methods and compositions for purifying antibodies. Purification is achieved by increasing the binding capacity of protein A chromatography by covalent attachment of a protein A domain (E, D, A, B, C), or domain Z, or a functional variant thereof, to Drosophila melanogaster transcription factor Ultrabithorax (Ubx) materials. The compositions include fusion proteins containing Drosophila melanogaster transcription factor Ultrabithorax (Ubx) or a fragment thereof and an immunoglobulin binding protein. In some embodiments, the immunoglobulin binding protein is a protein A domain, a protein Z domain or a fragment thereof.

The present invention relates to a novel immune-enhancing protein capable of enhancing antibody-forming ability, and use thereof. The vaccine composition comprising an antigen and a gPA-1-derived protein of Pneumocystis carinii or a gpl20-derived protein of human immunodeficiency virus (HIV), of the present invention, has an antibody-forming ability against a disease antigen that is superior to that of other vaccines, and thus a more effective vaccine can be prepared.

The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

The invention relates to a CD70-targeting antibody or a CD70-binding antigen binding fragment, and a preparation method and application of the CD70-targeting antibody or the CD70-binding antigen binding fragment. The antibody targeting CD70 or the antigen binding fragment binding CD70 can block CD70 / CD27 signals in a targeted manner, and kill cancer cells expressing CD70 by enhancing antibody-dependent cell-mediated cytotoxic effect, antibody-dependent cell-mediated phagocytosis and complement-dependent cytotoxic effect, so that immune monitoring on solid tumors is recovered.

The invention relates to the technical field of vaccine preparations, in particular to a preparation method and application of a pseudomonas aeruginosa DNA vaccine combined with a CpG-ODN adjuvant. The invention discloses a pseudomonas aeruginosa DNA vaccine combined with a CpG-ODN adjuvant. The pseudomonas aeruginosa DNA vaccine is prepared from the following raw materials: CpG oligonucleotide and a pseudomonas aeruginosa DNA vaccine. According to the technical scheme, the technical problems that an existing DNA vaccine is insufficient in immunogenicity, and effective immune response is difficult to induce can be solved. A synergistic effect is generated between the adjuvant and the vaccine, the secretion of cell factors is promoted, the antibody titer is improved, and the immune response effect is improved in the aspect of inducing the immune response of Th1 / Th2 / Th17 mixed cells. According to the technical scheme, a small-dose adjuvant is innovatively combined to enhance the immunogenicity of the vaccine, the immune efficacy of the vaccine and the safety of the vaccine are improved, and the novel DNA vaccine is simple in preparation method, remarkable in effect and ideal in application and popularization prospect.

Provided herein are methods and compositions for purifying antibodies. Purification is achieved by increasing the binding capacity of protein A chromatography by covalent attachment of a protein A domain (E, D, A, B, C), or domain Z, or a functional variant thereof, to Drosophila melanogaster transcription factor Ultrabithorax (Ubx) materials. The compositions include fusion proteins containing Drosophila melanogaster transcription factor Ultrabithorax (Ubx) or a fragment thereof and an immunoglobulin binding protein. In some embodiments, the immunoglobulin binding protein is a protein A domain, a protein Z domain or a fragment thereof.

The invention provides an application of tauroursodeoxycholic acid or an analogue thereof in preparation of an immunopotentiator of a vaccine, and the immunopotentiator. The application finds that tauroursodeoxycholic acid is an effective active component capable of activating immunity, enhancing antibody titer and shortening antibody generation reaction time, and can be widely applied to various vaccine immune processes. The bile acid metabolite and the derivative of the bile acid metabolite, which are analogues of tauroursodeoxycholic acid, also have immunological enhancement activity according to structural similarity.

To provide compositions and methods for augmenting antibody-mediated receptor signaling.SOLUTION: An engineered polypeptide comprises an Fc variant of a wild-type human IgG Fc region, where the Fc variant comprises amino acid substitutions at residue positions 228, 234, 235, 345, 409, 430, 440, or a combination thereof, and where the amino acid residues are numbered according to the EU index of Kabat.SELECTED DRAWING: Figure 1